Toxic leukoencephalopathy

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Investor, IND, Adult, Investment, Prostate cancer, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Trichloroethylene, PSMA, Nasdaq, Cluster, Webcast, Cytokine release syndrome, File, Research, Risk, MCRPC, Hand, Board, FUTURE, Half-life, Therapy, Human resources, TCE, PD-L1, News, Board of directors, Safety, FINANCIAL, CGMP, Pharmacokinetics, Cancer, Cowen, HR, Winston, Patient, Immune system, CD28, CEO, Security (finance), PD, Hematological Cancer Research Investment and Education Act, EGFR, Neurocrine Biosciences, Pharmaceutical industry, Dietary supplement, Management

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.
  • RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
    Janux has prioritized its programs to enable sufficient funding to provide key clinical data assessments for its lead programs.
  • THIRD QUARTER 2022 FINANCIAL HIGHLIGHTS:
    Cash and cash equivalents and short-term investments: As of September 30, 2022, Janux reported cash and cash equivalents and short-term investments of $338.8 million, compared to $375.0 million at December 31, 2021.
  • Net loss: For the quarter ended September 30, 2022, Janux reported a net loss of $16.7 million, compared to a net loss of $10.8 million for the comparable period in 2021.

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 4, 2022
MSD, Patient, EMA, FDA, Population, MD, United States patent law, Research, Cytokine, Annual report, Patent, Melanoma, SD, SITC, Company, CD122, GLOBE, Intellectual property, IND, NK, Toxic leukoencephalopathy, Immunotherapy, CEO, Renal cell carcinoma, Mission statement, Forward-looking statement, ID, PD, Society, Pharmacokinetics, EDGAR, Doctor of Philosophy, Method, 1836 U.S. Patent Office fire, MDNA, Annual general meeting, Biskit, Pancreatic cancer, International Cytokine & Interferon Society, Safety, GBM, CD25, Brain, Merck & Co., PR, USD, NASDAQ, IP, Pembrolizumab, United, News, SEDAR, GMP, Leukemia, Bifunctional, Mobile phone, Pharmaceutical industry, Vaccine, Security (finance), Cryptocurrency, Audit, Merck

TORONTO and HOUSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2022. All dollar amounts are in Canadian currency unless otherwise noted.

Key Points: 
  • The confirmatory scan for this patient showed further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy.
  • All patients in the trials dose escalation phase are treated with MDNA11 monotherapy via intravenous infusion every two weeks.
  • Under the terms of the agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA.
  • Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.

Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Company, Therapy, 2021 Essex County Council election, SAN, Society, GLOBE, ASH, Toxic leukoencephalopathy, APS, Acute myeloid leukemia, Transplant, TSX, Hematology, NASDAQ, Exposition, AML, Patient, Cancer, Cellular, Pharmaceutical industry, Dentistry, Blood

The abstracts accepted for presentation are listed below and can be viewed online at the ASH conference website .

Key Points: 
  • The abstracts accepted for presentation are listed below and can be viewed online at the ASH conference website .
  • Note that the actual presentations will include more recent updates and additional data not found in the abstracts.
  • Aptose will hold a Clinical Update webcast during the ASH timeframe to provide up-to-date data.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, November 3, 2022
ORR, Private Securities Litigation Reform Act, FGFR2, Hyperphosphatemia, Investment, HR, GLOBE, ESMO, D, Safety, Fulvestrant, Fourth grade, Toxic leukoencephalopathy, COVID-19, Nasdaq, Therapy, Research, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Risk, Diarrhea, Compte rendu, Security (finance), CCA, Patient, Drug discovery, Pharmaceutical industry, Dynamo

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2022 financial results and recent corporate highlights.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2022 financial results and recent corporate highlights.
  • We continue to deliver on our execution focus for 2022 and the third quarter uniquely exemplified this, said Sanjiv Patel, M.D., Relay Therapeutics president and chief executive officer.
  • Relay Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into 2025.
  • G&A Expenses: General and administrative expenses were $16.1 million for third quarter of 2022, as compared to $14.7 million for the third quarter of 2021.

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, Peripheral neuropathy, Journal, Private Securities Litigation Reform Act, Phase, Therapy, Neck, Medicinal chemistry, CD137, Biotechnology, MT1-MMP, BTC, Incidence, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Journal of Medicinal Chemistry, COVID-19, Esophageal cancer, Ovary, Head, Research, Molecular Cancer Research, Rash, Clinical trial, Cancer research, Forward-looking statement, Cancer, NASDAQ, American Association for Cancer Research, Non-small-cell lung carcinoma, Drug development, Risk, Program, Technology, Security (finance), Thromboxane A2, SEC, Treatment, Patient, Triple-negative breast cancer, Pharmaceutical industry, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, November 2, 2022
ACT, OCT, Floater, GLOBE, Industry, COVID-19, Eye, Investment, Compliance, Private Securities Litigation Reform Act, Annual general meeting, Company, FDA, Webcast, Aqueous humour, ASRS, Visual inspection, CEO, Toxic leukoencephalopathy, Centers for Medicare & Medicaid Services, U.S. FDA, Șaeș, Nasdaq, CST, Cleveland, Safety, NASDAQ, Investor, U.S. Securities and Exchange Commission, Patient, Therapy, Endophthalmitis, Retinal detachment, Federal, Inflammation, Clinical trial, CMS, SAFE, AAO, Processor register, Center, CALM, Treatment, AMD, Intellectual property, Retina, Retinal vasculitis, Medicare, AxoGen, Cleveland Clinic, Visual acuity, Forward-looking statement, Pharmaceutical industry, Video game

WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter endedSeptember 30, 2022and highlighted recent corporate developments.
  • The first patient was dosed in the Phase 2 PAVIA clinical trial of EYP-1901 for the treatment of NPDR in September 2022.
  • In October 2022, the Company and ImprimisRx mutually terminated an agreement for the commercialization of DEXYCU effective December 31, 2022.
  • EyePoint will host a conference call today, at8:30 a.m. ETto discuss the results for the third quarter ended September 30, 2022 and recent corporate developments.

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

Retrieved on: 
Tuesday, November 1, 2022
Annual report, Inhalation, Lung transplantation, Invasive, Toxic leukoencephalopathy, Nose, The Alfred Hospital, Tacrolimus, Lung, Government, FVC, Aspergillus, Azole, GLOBE, QT interval, Risk, FEV1, Skin, Freezing, Absorption, Powder, Drug, Mycosis, Safety, Technology, Vaccine, NASDAQ, Hair loss, Company, Voriconazole, FDA, IPA, History, Posaconazole, Patient, TFF, Therapy, Fatigue, Pharmaceutical industry

FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that a second patient has been successfully treated with TFF Pharmaceuticals’ proprietary Voriconazole Inhalation Powder (“TFF VORI”) through a compassionate use program. This is the second patient to receive TFF VORI at the Alfred Hospital in Melbourne, Australia. In September, Dr. Bradley Gardiner presented data from the first patient successfully treated with TFF VORI at the 15th Annual International Congress on Lung Transplantation.

Key Points: 
  • FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc.(NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that a second patient has been successfully treated with TFF Pharmaceuticals proprietary Voriconazole Inhalation Powder (TFF VORI) through a compassionate use program.
  • In September, Dr. Bradley Gardiner presented data from the first patient successfully treated with TFF VORI at the 15th Annual International Congress on Lung Transplantation.
  • TFFs proprietary Thin Film Freezing technology platform allows for the reformulation of voriconazole into a dry powder with properties ideally suited for inhalation.
  • During the ongoing compassionate use program, a second lung transplant patient has been successfully treated with TFF VORI.

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), TAC, Toxicity, European Society of Gynaecological Oncology, Breast cancer, EORTC, Aileron, Toxic leukoencephalopathy, U.S. Securities and Exchange Commission, Tissue, Annual report, Dermatology, Conference, Clinical trial, Cancer, GLOBE, Doxorubicin, Bone marrow, Nasdaq, R, Administration, Thrombocytopenia, Anemia, G&A, Cyclophosphamide, Coronavirus, Doctor of Science, Form 10-K, Neutropenia, University, B cell, Investment, ALRN, Research and development, Private Securities Litigation Reform Act, Annual general meeting, Therapy, ESDR, Pharmacokinetics, Patient, Serum, Medicine, Cell cycle, Docetaxel, FRSB, Medical imaging, Pharmaceutical industry

Aileron plans to report initial data from the breast cancer trial in 4Q 2022, an interim readout in 2Q 2023, and topline results in 3Q 2023.

Key Points: 
  • Aileron plans to report initial data from the breast cancer trial in 4Q 2022, an interim readout in 2Q 2023, and topline results in 3Q 2023.
  • Presented detailed results from Phase 1 study in healthy volunteers at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
  • Net Loss: Net loss for the quarter ended September 30, 2022, was $6.4 million, compared to $6.7 million for the corresponding quarter in 2021.
  • The basic and diluted net loss per share for the third quarter of 2022 was $0.07 compared to $0.07 for the third quarter of 2021.

Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

Retrieved on: 
Wednesday, October 26, 2022
Breast cancer, Pharmacokinetics, Securities Exchange Act of 1934, ENA, DNA, Trial of the century, Cancer, Neutropenia, Safety, Investor, U.S. Securities and Exchange Commission, Fast track (FDA), CDK, Fatigue, Research, Poster, Webcast, Trae tha Truth, Patient, Fulvestrant, Nausea, Overalls, SERD, RECIST, GLOBE, Woman, Neoplasm, ER, Review, ESR1, Securities Act of 1933, Sarah Cannon Research Institute, Ribociclib, Drug Quality and Security Act, Half-life, Toxic leukoencephalopathy, Incidence, Vomiting, Circulating tumor DNA, Oncology nursing, Pharmaceutical industry, Medical imaging

ET

Key Points: 
  • ET
    SAN FRANCISCO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology or the Company, Nasdaq: OLMA) today announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Companys complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer.
  • We believe in the potential of OP-1250, and we look forward to initiating our first pivotal Phase 3 trial mid-next year.
  • Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers.
  • Olemas lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).

Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

Retrieved on: 
Tuesday, October 18, 2022
Toxic leukoencephalopathy, MDS, Company, Lymphatic system, Patient, Hematology, Investor relations, Webcast, Mission statement, PIN, EDGAR, Acute myeloid leukemia, Q&A, Call Me, AML, SEDAR, Pharmaceutical industry

They also will have the option to take advantage of a new Call Me button and the system will automatically dial out to connect to the Q&A session.

Key Points: 
  • They also will have the option to take advantage of a new Call Me button and the system will automatically dial out to connect to the Q&A session.
  • The audio webcast can also be accessed through a link on the Investor Relations section of Aptoses website here .
  • The press release, the financial statements and the managements discussion and analysis for the quarter ended September 30, 2022 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.